Singapore markets closed

Nabriva Therapeutics plc (NBRVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00000.0000 (0.00%)
At close: 11:44AM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
Total revenue
29,387
35,668
27,216
2,864
Cost of revenue
34,277
28,581
13,148
766
Gross profit
-4,890
7,087
14,068
2,098
Operating expenses
Research development
10,369
14,263
12,630
15,102
Selling general and administrative
34,624
45,264
51,645
55,285
Total operating expenses
44,823
58,260
62,596
68,224
Operating income or loss
-49,713
-51,173
-48,528
-66,126
Interest expense
-
698
901
1,649
Total other income/expenses net
-4,032
-3,746
469
-1,570
Income before tax
-54,224
-55,617
-48,960
-69,345
Income tax expense
830
1,568
490
139
Income from continuing operations
-55,054
-57,185
-49,450
-69,484
Net income
-55,054
-57,185
-49,450
-69,484
Net income available to common shareholders
-55,054
-57,185
-49,450
-69,484
Basic EPS
-18.37
-21.32
-28.52
-135.23
Diluted EPS
-18.37
-21.32
-28.52
-135.23
Basic average shares
3,075
2,682
1,734
513.804
Diluted average shares
3,075
2,682
1,734
513.804